BioSpace News Archive

The partnership will allow Saama to accelerate its strategic initiatives, including expanding its go-to-market capabilities and further investing in AI research and development.

Axalbion today announced that the first patients have been treated in a Phase 2 clinical study in chronic cough with AX-8, its lead compound. AX-8 is a potent and selective oral agonist of the transient receptor potential melastatin 8 (TRPM8) ion channel.

CANbridge Pharmaceuticals Inc. announced that the Investigational New Drug (IND) application for CAN103 has been approved by the Chinese National Medical Products Administration (NMPA).

Immunome, Inc. today announced that it submitted to bioRxiv a preprint of a manuscript regarding preclinical research of the company’s SARS-CoV-2 antibody cocktail, IMM-BCP-01.

Radius Health, Inc. (NASDAQ: RDUS) announced today that it will release its third quarter financial results on Monday, November 8, 2021.

IceCure Medical Ltd. (Nasdaq: ICCM) (TASE: ICCM) (“IceCure” or the “Company”), today announced that it has entered into an initial distribution agreement with Mobile SCANMED Systems SP. z o.o. (“Mobile SCANMED Systems”) to exclusively sell the Company’s ProSense™ Cryoablation System and disposables in Poland.

Both Scientific Solutions Inc. and Management Solutions will be attending the 10th Annual MJBizCon in Las Vegas this week.

Viome Life Sciences, today announced the expansion of its two-year partnership with GSK, a science-led global healthcare company, to expand clinical research activities1 and potential development of new therapeutic interventions within the fields of chronic diseases including autoimmune diseases and cancers.

Asensus Surgical, Inc., a medical device company that is digitizing the interface between the surgeon and patient to pioneer a new era of Performance-Guided Surgery™, announced that it plans to release 2021 third quarter financial and operating results after the market closes on Wednesday, November 3, 2021.

Oct. 20, 2021 13:00 UTC Aatru Medical, LLC (“Aatru”) today announced the successful completion of the first 14 patients in their multi-center New Zealand-based clinical study of the FDA-approved NPSIMS™ Negative Pressure Surgical Incision Management System.